文献速递临床试验与 GCP流行病学与生物统计

治疗性肝素与预防性肝素对住院中症COVID-19患者死亡、机械通气或ICU入住的有效性:RAPID随机临床试验

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.
PubMed 文献 · BMJ · 2021-10-14

RAPID随机对照试验纳入465例住院中症COVID-19且D-二聚体升高的成人患者,比较治疗性肝素与预防性肝素。28天主要复合终点(死亡、机械通气或ICU入住)两组无显著差异(OR 0.69,95%CI 0.43-1.10;P=0.12),但治疗性肝素组死亡风险显著降低(1.8% vs 7.6%;OR 0.22,95%CI 0.07-0.65;P=0.006),大出血风险低且两组无显著差异。

要点

  • 治疗性肝素未显著降低主要复合终点(死亡、机械通气或ICU入住)风险。
  • 治疗性肝素组28天死亡风险显著低于预防性肝素组(1.8% vs 7.6%)。
  • 大出血发生率低,两组无显著差异(0.9% vs 1.7%)。

核心结论

  • 在住院中症COVID-19且D-二聚体升高的患者中,治疗性肝素未显著降低主要复合终点,但28天死亡风险显著降低。

研究设计与样本

  • 随机对照、适应性、开放标签临床试验,在巴西、加拿大、爱尔兰、沙特阿拉伯、阿联酋和美国的28家医院进行。
  • 2020年5月29日至2021年4月12日纳入465例住院中症COVID-19且D-二聚体升高的成人患者,随机分配至治疗性肝素组(n=228)或预防性肝素组(n=237)。

主要发现

  • 28天主要复合终点(死亡、有创机械通气、无创机械通气或ICU入住)在治疗性肝素组发生37/228例(16.2%),预防性肝素组52/237例(21.9%)(OR 0.69,95%CI 0.43-1.10;P=0.12)。
  • 28天死亡在治疗性肝素组4例(1.8%),预防性肝素组18例(7.6%)(OR 0.22,95%CI 0.07-0.65;P=0.006)。
  • 全因死亡或任何机械通气的复合终点在治疗性肝素组23例(10.1%),预防性肝素组38例(16.0%)(OR 0.59,95%CI 0.34-1.02;P=0.06)。
  • 静脉血栓栓塞在治疗性肝素组2例(0.9%),预防性肝素组6例(2.5%)(OR 0.34,95%CI 0.07-1.71;P=0.19)。
  • 大出血在治疗性肝素组2例(0.9%),预防性肝素组4例(1.7%)(OR 0.52,95%CI 0.09-2.85;P=0.69)。

临床怎么用

  • 对于住院中症COVID-19且D-二聚体升高的患者,治疗性肝素可考虑用于降低死亡风险,但需权衡出血风险。

局限性

  • 开放标签设计可能引入偏倚,主要终点未达统计学显著性,事件数较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. DESIGN: Randomised controlled, adaptive, open label clinical trial. SETTING: 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US. PARTICIPANTS: 465 adults admitted to hospital wards with covid-19 and increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237). INTERVENTIONS: Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death. MAIN OUTCOME MEASURES: The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care unit, assessed up to 28 days. The secondary outcomes included all cause death, the composite of all cause death or any mechanical ventilation, and venous thromboembolism. Safety outcomes included major bleeding. Outcomes were blindly adjudicated. RESULTS: The mean age of participants was 60 years; 264 (56.8%) were men and the mean body mass index was 30.3 kg/m2. At 28 days, the primary composite outcome had occurred in 37/228 patients (16.2%) assigned to therapeutic heparin and 52/237 (21.9%) assigned to prophylactic heparin (odds ratio 0.69, 95% confidence interval 0.43 to 1.10; P=0.12). Deaths occurred in four patients (1.8%) assigned to therapeutic heparin and 18 patients (7.6%) assigned to prophylactic heparin (0.22, 0.07 to 0.65; P=0.006). The composite of all cause death or any mechanical ventilation occurred in 23 patients (10.1%) assigned to therapeutic heparin and 38 (16.0%) assigned to prophylactic heparin (0.59, 0.34 to 1.02; P=0.06). Venous thromboembolism occurred in two patients (0.9%) assigned to therapeutic heparin and six (2.5%) assigned to prophylactic heparin (0.34, 0.07 to 1.71; P=0.19). Major bleeding occurred in two patients (0.9%) assigned to therapeutic heparin and four (1.7%) assigned to prophylactic heparin (0.52, 0.09 to 2.85; P=0.69). CONCLUSIONS: In moderately ill patients with covid-19 and increased D-dimer levels admitted to hospital wards, therapeutic heparin was not significantly associated with a reduction in the primary outcome but the odds of death at 28 days was decreased. The risk of major bleeding appeared low in this trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT04362085.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021. PMID: 34649864. doi:10.1136/bmj.n2400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。